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LIOBLASTOMAS are the most common and malignant adult primary intracranial tumors. The dismal clinical prognosis reflects difficulties in elucidating transformation processes in glioma cells by means of available animal models. ~~ In the investigation of glioma biology, characteristics determined in fresh tumor samples nonetheless provide the most realistic reflection of the native state. Most cells in primary tumors are diploid or near-diploid. 4' 6"3~32 Phenotypically, gliomas often express the glial fibrillary acidic protein (GFAP) and some are tumorigenic in nude mice) 9 Upon establishment of glioma cells in culture, however, development of tetraploidia with the gain of one No. 7 chromosome and multiple double minutes or the loss of one No. 22 chromosome are common, 6 This suggests that growth advantage may have a genetic basis. In established tumor lines, specific growth and biochemical (for example, GFAP expression) properties are displayed.~ 3. 18, 19, 30, 40 In particular, anchorage-independent growth of these tumor lines is the best predictor of tumorigenic potential in nude mice? These characterizations thus provide the framework for investigations involving oncogenes and growth factors, which are central to the transformation process.
Cell transformation is a multi-step process involving the activation of proto-oncogenes. TM 1, 12, 22, 23, 35, 39, 41 Among these genes, the epidermal growth factor-receptor (EGF-R) gene is amplified in a great number of human glioblastomas and remains the only protooncogene consistently overexpressed in glioblastomas. 14, 27,28,36 Thus, the EGF-R gene appears to be linked to glial transformation. Enhanced EGF-R gene expression appears to confer a growth advantage in other malignancies5938 In human epidermoid carcinoma A-431 and human breast carcinoma MDA-468 cells, enhanced EGF-R activation results in growth inhibition while reduced activation stimulates cell proliferation. ~ 3,~6., 7, 20 Thus, when the epidermal growth factor (EGF) is limited, increased EGF-R's would confer a growth advantage. In particular, blockage of EGF-R activation appears to inhibit tumor development and growth. 33 This supports a role for the overexpressed EGF-R in tumor formation. Whether a similar action occurs in glioblastomas to provide a functional relationship between a proliferation-modulating mechanism by the EGF-R and glial tumorigenesis is, however, not clear. Such a role for the EGF-R and/or other proto-oncogene products must first be established before further investigations of the mechanisms involved are undertaken. In some primary gliomas and some tumorigenic lines, EGF-R gene expression is not significantly enhanced. In these cells, the EGF-R gene may be altered to give a continuous growth signal (as in erb-B). Alternatively, the EGF-R gene may not subserve functions directly associated with growth modulation. Since tumor formation represents an aspect of the arrest or loss of full differentiation, association of the EGF-R gene with glioblastomas may imply a role of this gene in glial differentiation. In this capacity, it may function alone or in concert with other proto-oncogenes to maintain the transformed glial cell in a proliferation-competent state, and indirectly contribute to its progression to tumorigenicity. This report describes investigation results indicating that EGF-R gene overexpression does not correlate directly with glioblastoma tumorigenesis as measured by tumor formation after glioma cells were inoculated subcutaneously in nude mice. Thus, the EGF-R gene may participate in glioblastoma oncogenesis in ways other than growth promotion. Further investigations of proto-oncogene abnormalities in neuroectodermal tumors suggest that tumors of neuronal and glial origin manifest distinct and nonoverlapping patterns of protooncogene expression. This suggests that they may not share a common oncogenic pathway. Since oncogenesis also involves differentiation arrest, the EGF-R gene may thus be implicated in glial differentiation.
Materials and Methods

Cell Lines and Tumors
The glioblastoma cell lines used in this study were U373MG, U87MG, A172, HS683, and T98G. Glioma tumor tissue was obtained at the University of California, San Diego (UCSD) and at the Veterans Administration Medical Center, San Diego, and included six glioblastoma samples identified as GB-TI, GB-T2, GB-T3, GB-T4, GB-Ts, and GB-T6, and one grade II astrocytoma sample, G-II-Tj. The neuroblastoma cell lines used were SKN-C and Lan-5. 24 The SKN-C cells were a subpopulation of the SN-SH neuroblastoma cells. The retinoblastoma cell line Y-79 was examined together with two primary retinoblastomas (SD RB-1 and SD RB-2), both obtained at UCSD. The neuroblastoma, retinoblastoma, and glioblastoma cell lines were obtained from the American Type Culture Collection.
Anchorage Dependence of Glioblastoma Cell Growth
The anchorage dependence of glioblastoma cell growth, the best in vitro correlate to tumorigenesis in the nude mouse, was determined in the soft agar assay. 5 This assay is a determination of the ability of cells to form colonies when cultured in a suspension of soft agar, an environment which prevented the cells from attaching to the culture dish. In this analysis, 1000 to 2000 cells from each of the cell lines were suspended in 3 ml of either Dulbecco's modified Eagle's medium or minimum essential medium supplemented with 10%
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fetal calf serum (FCS), both of which had been mixed with agar (0.25%). The suspension was placed on a base layer composed of the same medium mixed with agar (0.5%) in a 60-mm dish. Each line was evaluated in triplicate. The cultures were maintained at 37~ and placed in fresh medium every 6 days. At the end of 2 weeks, colonies composed of greater than 20 cells were scored in 25 random fields which comprised 1.5% of the total dish area.
Determination of Tumorigenic Potential of Glioblastoma Cell Lines
Cells in culture were evaluated for their tumorigenic potential in the nude mouse. In preliminary studies, the tumorigenic potential of the different cell lines in the nude mice were evaluated by the subcutaneous inoculation of between 1 • 10 6 and 1 • 107 cells. Consistent results were obtained for each inoculum size. Therefore, in the tumorigenic assay in this study, the dose of 5 • 10 6 cells was chosen. Cells were suspended in media without FCS and inoculated subcutaneously. Four animals were inoculated with each cell line. Each animal was observed for 3 months before any inoculum was declared nontumorigenic. When tumors formed at the site of injection, the latency of tumor formation was recorded.
Analyses of DNA and RNA
Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) were extracted from both tumor and cell culture tissues by established techniques. 24"3~ The DNA samples were subjected to Southern blot and slot blot analysis. For Southern blot analysis, each DNA sample (10 izg) was digested to completion with an excess of the restriction endonucleases EcoR 1 or BamH 1 and fractionated by electrophoresis in a 0.8% agarose gel before transfer to nitrocellulose membranes. Hybridization with each 32p-labeled probe was performed in buffer composed of 50% formamide, 5 units of Denhardt's solution (0.02% Ficoll solution, 0.02% polyvinylpyrrolidone, and 0.02 % bovine serum albumin), 6 units of standard saline citrate (SSC), 0.1% sodium dodecyl sulfate (SDS), 1 mM sodium phosphate, pH 7.5, and 200 ug/ml salmon sperm DNA. Each wash was carried out at high stringency (for 30 minutes in 2 units of SSC + 0.1% SDS at 22~ and for 60 to 120 minutes in 0.1 units of SSC + 0.1% SDS at 65~
The filters were then autoradiographed at -70~ for 3 to 4 days using intensifier screens.
For slot blot analysis, DNA samples were first denatured in 0.1 N NaOH at 100~ for 10 minutes, neutralized in 0.1 N HC1, and then serially diluted to samples of 10, 5, 1, and 0.1 vg in 10 units of SSC (100 vl volume) for direct blotting onto nitrocellulose membranes using the slot blot Minifold II.* Hybridization and washing conditions were identical to those de-scribed above. In studies of neuroectodermal tumors, the same blot was analyzed using the N-myc and EGF-R gene probes.
Messenger RNA expression was analyzed with slot blotting analysis. Total RNA was isolated by the guanidine thiocyanate/CsC1 method? ~ Samples were serially diluted in 20 units of SSC to 10, 5, and 1 ug before being applied in 100-#1 volumes directly onto nitrocellulose membranes; analysis was performed as described above in the DNA blotting analysis.
In the DNA and RNA slot blot analysis, the magnitude of gene amplification and expression was assessed by densitometry. The specific gene probes emDloyed included v-myc, H-ras, v-sis, v-fos, neu, EGF-R, human transferrin receptor (HTR), and N-myc.t For detection of EGF-R sequences, the 0.8-kilobase-pair (kbp) EcoR 1 fragment was used and, for detection of the neu oncogene, the 420-bp BamH1 fragment was prepared from plasmid neu (t)/sp6400.:~ The 1-kbp BamH1-EcoR 1 fragment for N-myc was prepared from the Nmyc (pNb-1) probe for ~2p labeling. Each probe was labeled with 32p-deoxyadenosine triphosphate by nick translation .~4 ~,,
Results
Anchorage Dependence of Glioblastoma Cell Growth
The anchorage dependence of glioblastoma cell lines was evaluated in soft agar. In this analysis, colonies formed in U373MG, U87MG, and T98G cultures. None was observed in the A172 or HS683 cultures ( Table 1 ) .
Tumorigenicity of Glioblastoma Cell Lines
The five glioblastoma cell lines were tested for tumorigenicity in the nude mouse after injecting 5 x 106 cells subcutaneously into the scapular and flank regions of each animal. Four animals were injected with each cell line. Large hemorrhagic cystic tumors were formed by U373MG cells while solid tumors arose from U87MG cells after a latency of 3 weeks. A small nodule arose subcutaneously in one mouse injected with T98G cells. This nodule did not grow progressively despite prolonged incubation (4 months), which demonstrated that the tumorigenic potential of T98G cells was not as remarkable as that of U373MG and U87MG cells. No tumors formed from the A172 and HS683 injections. Thus, a spectrum of tumorigenic potential was observed in the five cell lines, and tumorigenicity correlated with anchorage-independent growth (Table 1) .
t The v-myc, H-ras, v-sis, and v-fos probes were gifts of W. H. Lee, University of California, San Diego, California; the HTR probe was a gift from F. Ruddle, Yale University, New Haven, Connecticut.
EcoR1 was a gift of G. Gill, University of California San Diego, California; the neu probe was a gift from R. Weinberg, Massachusetts Institute of Technology, Cambridge, Massachusetts. , which is equivalent to 1.7% of the total culture area for each dish. + = positive: +_ = equivocal: -= negative.
Gross Abnormalities of Proto-Oncogenes in Glioblastomas
Seven glial tumors (six glioblastoms and one grade II astrocytoma) and five glioblastoma cell lines were analyzed by DNA and RNA blotting analysis with the EGF-R, v-fos, N-myc, v-sis, v-myc, c-myc, neu, H-ras, and HTR gene probes.
Genomic DNA from the primary human gliomas and cell lines was subjected to Southern blot analysis. The EGF-R gene was significantly amplified (six-to 12-fold) in two of the six glioblastomas. In two other primary glioblastomas, GB-T~ and GB-Ts, respectively, twice and three times the normal copy number of the EGF-R gene was observed. No increase in the gene copy number or gene amplification was detected in the grade II astrocytoma. In one cell line (A172), the gene copy number was also increased twofold (Fig. 1) . The EcoR1 fragments in these glioma and cell line samples (3.5, 5.2, and 7.7 kbp in size) were identical to those in normal tissues. No additional fragments were detected (Fig. 1A) .
When the RNA obtained from these tissues was subjected to slot blot analysis, the EGF-R gene was observed to be expressed in all primary glioblastomas from 11-to 62-fold higher than in the control (Fig. 2) . Expression of the EGF-R gene was, however, at a relatively low level (five times the control level) in the cell line where the gene copy number was doubled (A 172). In another cell line without an amplified EGF-R gene (T98G), elevated expression (36-fold) was detected. While the expression of the HTR gene was not prominent in glial tumors and cell lines, one tumor (GB-T4) and four cell lines nonetheless expressed the HTR gene in slightly elevated amounts (four to five times the control level) (Fig. 3) . In addition to these two receptor genes, a panel of proto-oncogenes such as vfos, N-myc, v-sis, v-myc, c-myc, neu, and H-ras was also employed in this analysis to determine any changes in these genes in glioblastomas. None of these genes was amplified or overexpressed in any glioblastoma tumor or cell line, with the possible exception of v-fos which demonstrated elevated expression in one glioblastoma cell line (U373MG) (data not shown). In particular, the v-sis and v-myc genes were neither amplified nor overexpressed in this analysis.
The correlation between the tumorigenic potential of each line and the absolute level of EGF-R gene expression was therefore found to be unclear in this analysis. This suggests that, even though the EGF-R gene is implicated in glioblastoma tumorigenesis, it may not play a direct role in conferring the tumorigenic potential in transformed glial cells. Since tumorigenesis also involves differentiation arrest, we explored whether the EGF-R gene might be involved in glial transformation in ways other than growth modulation, such as in glial differentiation from its precursor in the neuroectoderm. In this regard, the patterns of proto-oncogene abnormalities in tumor cells derived from components of the neuroectoderm --neurons and glia --were determined to ascertain if specific proto-oncogenes were involved in each subgroup of neuroectodermal tumors.
Differential Proto-Oncogene Amplification and Expression in Neuroectodermal Tumors
The genomic D N A and total R N A derived from two neuroblastoma cell lines (SKN-C and Lan-R), 24 one retinoblastoma line (Y-79), and two retinoblastoma tumors (SD RB-1 and SD RB-2) were subjected to slot blot analysis using the N-myc, EGF-R, and H T R probes ( Table 2 ). The N-myc gene was amplified in Lan-5 (71-fold), Y-79 (26-fold), and SD RB-2 (39-fold) (Fig. 4A) . In addition to being overexpressed in these three tissue samples (5.5-to 22-fold), expression was also elevated sevenfold in the primary retinoblastoma t u m o r SD RB-1, in which the gene was not amplified (Fig. 5A) . When FIG. I. A: Southern blot analysis of the epidermal growth factor-receptor (EGF-R) gene in primary glioblastoma DNA samples. Amplification of the gene was observed, especially in GB-T2 and GB-T3. The EcoR1 fragments were of the same size as observed with other glioblastoma samples and the U373MG cell line as well as in the control DNA sample derived from the human placenta (HPL). DNA quantitation in each lane was assessed using the N-myc probe since no Nmyc amplification was observed in any of the gliomas. Equivalent amounts of DNA were demonstrated in each lane. KB = kilobase. B: Slot blot analysis of the EGF-R gene in primary glioma and glioblastoma cell line DNA samples. Each sample was serially diluted to contain 10, 5, 1, and 0.1 ug of DNA. Amplification of the EGF-R gene, determined by densitometry, was observed in the primary tumors GB-T2 (12-fold) and GB-T3 (sevenfold). The EGF-R gene copy number was also increased in GB-T~ (twofold), GB-T5 (threefold), and the cell line A172 (twofold). DNA derived from a normal human pituitary gland (SR) was used for control data, and the intensity observed was standardized to 1 when the degree of amplification was calculated in the tumor samples. UG = micrograms.
FIG. 2.
Slot blot analysis of epidermal growth factor-receptor (EGF-R) expression in glioma tumor samples and glioblastoma cell lines. Overexpression of EGF-R RNA (44-to 62-fold) was demonstrated in the primary glioblastoma samples (GB-T2 and GB-T3) where the gene was significantly amplified. Gene expression was also increased in GB-T~, GB-T4, and GB-T5 (11-to 24-fold). No overexpression was seen in A 172. In cell line T98G, which did not possess an amplified gene, the receptor was overexpressed (36-fold). Samples from normal human fibroblasts (SD RB) were used for control data, and the intensity observed was standardized to 1 when overexpression in the tumor samples was calculated. The GB-T6 cell line was not included due to inadequate amounts of the samples available. UG = micrograms. the genomic DNA and RNA derived from these neuroblastomas and retinoblastomas were analyzed with the EGF-R gene probe, no amplification (Fig. 4B) or elevated expression of the EGF-R gene (Fig. 5B) tFor evaluation of N-myc amplification and expression, SKN-C was used as the control and its intensity on the blots was standardized to 1 for comparison.
For evaluation of epidermal growth factor-receptor (EGF-R) gene amplification, GB-T4 was the control tissue while for EGF-R expression, U87MG was the control tissue, since amplification or overexpression was not observed in this cell line.
detected. The reverse was observed when glioblastoma DNA and RNA were analyzed with the N-myc and EGF-R gene probes. There data indicated that the Nmyc and EGF-R genes were exclusively amplified and overexpressed in either neuronal tumors (retinoblastomas and neuroblastomas) or glial tumors (glioblastomas). Despite the common origin from the neuroectoderm of these two tissue types, no overlap in N-myc and EGF-R gene expression was observed in the respective tumors.
When genomic DNA from these tissues was hybridized with the HTR gene probe, no gross abnormality such as amplification or translocation was observed. Expression of HTR messenger RNA was observed in some samples derived from both tissue types but did not follow any specific pattern.
Discussion
In this study, amplification and enhanced expression of the EGF-R gene was demonstrated in most glioblas- FIG. 3 . Slot blot analysis of h u m a n transferrin receptor ( H T R ) gene expression in glioma a n d glioblastoma cell line R N A samples. Overexpression was observed in the prim a r y glioblastoma (GB-T4) (fourfold) and in the U 3 7 3 M G , U 8 7 M G , HS683, and T 9 8 G cell lines (4.5-to fivefold). Normal fibroblast R N A derived from a patient with a retinoblast o m a (SD RB) was used for control data. U G = micrograms. and SD RB-2), three p r i m a r y glioblastomas (GB-T3, GB-T4, a n d GB-T~), a n d three glioblastoma cell lines ( U 3 7 3 M G , U 8 7 M G , and T98G). U G = m i c r o g r a m s .
A: W h e n 32p_ labeled N -m y c was used as a probe, amplification of the gene in Lan-5 (71-fold), Y-79 (26-fold), and SD RB-2 (39-fold) was evident. In contrast, n o n e o f the glioma samples d e m o n s t r a t e d any amplification. In calculating the m a g n i t u d e of amplification, the intensity observed in S K N -C , where no gene amplification was observed, was standardized to 1, according to Lee, et al. ~4 B: W h e n 32p-labeled epidermal growth factorreceptor (EGF-R) was used as a probe, eightfold amplification of the E G F -R gene was observed in GB-T3, while the gene copy n u m b e r was increased threefold in GB-Ts. N o such amplification was observed in GB-T~. T h e intensity of the b a n d in GB-T4 was therefore standardized to 1. toma cells. However, neither amplification nor enhanced expression of the EGF-R gene correlated well with the ability of glioblastoma cells to form colonies in soft agar or their tumorigenic potential in the nude mouse. Thus, the EGF-R gene is likely involved in glioma transformation in ways other than direct growth modulation. In order to further define the role of the EGF-R gene in glioma biology (for instance, in glial cell differentation), proto-oncogene abnormalities in neuronal and glial tumors were analyzed, since these two cell types are both derived from the neuroectoderm. Exclusive amplification and enhanced expression of the N-myc and EGF-R genes were detected in neuroblastomas/retinoblastomas and glioblastomas, respectively. The distinct association of N-myc with neuronal tumors and the EGF-R with glial tumors is striking in view of their common origin from the neuroectoderm. 15 ' 25' 26 These data suggest that neuronal and glial FIG. 5. Slot blot analysis of total RNA samples obtained from the neuroblastoma, retinoblastoma, and glioma samples as listed in Fig. 4 to evaluate the degree of N-myc and epidermal growth factor-receptor (EGF-R) gene expression. UG = micrograms. A: N-myc gene overexpression was not only observed in Lan-5 (sixfold) and SD RB-2 (19-fold), in which the gene was amplified, it was also overexpressed in SD RB-1 (sevenfold), where no gene amplification was seen. Nmyc was again overexpressed in Y-79 cells (22-fold) as previously demonstrated. 24 No such overexpression was observed with the gliomas. In calculating the degree of gene expression, the expression in SKN-C (in which no overexpression was observed) was standardized to 1. B: In contrast to the pattern of N-myc gene expression, the EGF-R gene was only overexpressed in glioblastoma GB-T3 (eightfold) where gene amplification was observed, and in GB-T5 (fourfold) and T98G (10-fold) where no amplification was detected (see Fig. 4B ). No overexpression of EGF-R was demonstrable in any neuroblastoma or retinoblastoma sample. In this analysis, the expression in U87MG was standardized to 1 since no enhanced expression of the EGF-R was observed in this cell line. transformation may follow different oncogenic pathways. Since tumor formation is also associated with differentiation arrest, these genes may be implicated in the divergent differentiation of neurons and glia as well.
Proto-oncogene activation has been implicated in the oncogenesis of human malignancies. 7-9"~ 1. 12, 22, 23, 35, 39, 41 This is suggested by the amplification and enhanced expression of specific oncogenes in selective tumors (such as N-myc in neuroblastomas and retinoblastomas). 2a Thus, the amplification of the EGF-R gene in glioblastomas implies that it is involved in glial oncogenesis. The exact role that the EGF-R plays in this process is unknown. The fact that the EGF-R is a growth factor receptor suggests its involvement in modulating the growth response of glioblastoma cells to EGF, as is observed in human epidermoid carcinoma (A-431) cells with a similarly amplified and overexpressed EGF-R gene. 17.2o.29.38 In A-431 cells, EGF at low doses is growth-stimulatory while maximum EGF-R stimulation (with high doses of EGF) is growth-inhibitory. If a similar EGF-R mechanism exists in glioblastoma cells, a biphasic growth response to EGF would be expected. This, however, has not been observed in multiple cell lines with varying degrees of EGF-R gene expression (our unpublished observations). To further delineate the association of other growth properties with an overexpressed EGF-R, the growth of these cell lines was characterized in soft agar and in the nude mouse. In these investigations, no direct correlation between these growth properties and the absolute level of EGF-R expression was observed. In particular, cell lines that did not possess an overexpressed EGF-R (U373MG and U87MG) were extremely tumorigenic. This lack of direct correlation between in vitro and in vivo growth and the level of EGF-R expression is not likely a result of the heterogeneity of the cell lines injected. In a mixed cell population, tumors which are formed after their inoculation into the nude mouse are expected to be composed primarily of the subpopulation(s) showing the greatest tumorigenic potential or the most aggresive growth. These subpopulations are also expected to be dominant in tissue culture. Characteristics determined in cell culture are therefore expected to reflect properties of these dominant tumor-forming cell groups. The lack of EGF-R overexpression in them therefore suggests that the EGF-R may not be primarily responsible for their tumorigenic potential. An alternative explanation is that cells lacking an overexpressed EGF-R may nevertheless up-regulate the receptor after their inoculation into nude mouse so as to afford the cells tumor-forming capability. This also appears unlikely since some primary glioblastomas excised from patients do not demonstrate an overabundance of EGF-R's. Thus, the role of the activated proto-oncogene EGF-R in glial tumorigenesis remains ill-defined.
In DNA transfection studies, certain transformation activities have been identified in selective oncogenes. 9-2223 In these investigations, it was demonstrated that one gene alone was limited in conferring the fully transformed state to a cell. A number of proto-oncogenes, each acting at different stages of the growthstimulating pathway, may need to be involved for full tumorigenic transformation to take place. Thus, it is likely that the EGF-R gene, when acting to modulate glial differentiation, cooperates with other genes to promote glial tumorigenesis. Genes that might cooperate with the EGF-R gene include c-myc, 37 gli,~" or fos and HTR (our unpublished observation). In particular, the HTR may function like the EGF-R to mediate a growth or differentiation effect and, as such, may behave like a proto-oncogene which, acting in concert with other proto-oncogenes, would effect transformation.
In summary, the lack of correlation between EGF-R gene amplification and enhanced expression with the tumorigenic potential of glioblastoma cells suggests that the role of the EGF-R in glioblastoma biology may not be direct growth modulation. Analysis of proto-oncogene abnormalities in neuroectodermal tumors suggests that the EGF-R may participate in the developmental arrest of glial cells.
